No difference in human mast cells derived from peanut allergic versus non-allergic subjects.

Autor: Larsen LF; Allergy Clinic, Copenhagen University Hospital Gentofte, Copenhagen, Denmark., Juel-Berg N; Allergy Clinic, Copenhagen University Hospital Gentofte, Copenhagen, Denmark., Hansen A; Medical Prognosis Institute, Hoersholm, Denmark., Hansen KS; Allergy Clinic, Copenhagen University Hospital Gentofte, Copenhagen, Denmark., Mills ENC; Division of Infection, Immunity and Respiratory, School of Biological Sciences, Manchester Institute of Biotechnology, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK., van Ree R; Departments of Experimental Immunology and of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Rådinger M; Department of Internal Medicine and Clinical Nutrition, Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden., Poulsen LK; Allergy Clinic, Copenhagen University Hospital Gentofte, Copenhagen, Denmark., Jensen BM; Allergy Clinic, Copenhagen University Hospital Gentofte, Copenhagen, Denmark.
Jazyk: angličtina
Zdroj: Immunity, inflammation and disease [Immun Inflamm Dis] 2018 Dec; Vol. 6 (4), pp. 416-427. Date of Electronic Publication: 2018 Jul 10.
DOI: 10.1002/iid3.226
Abstrakt: Introduction: Mast cells are the primary effector cells of allergy. This study aimed at characterizing human peripheral blood-derived mast cells (PBdMC) from peanut allergic and non-allergic subjects by investigating whether the molecular and stimulus-response profile of PBdMC discriminate between peanut allergic and healthy individuals.
Methods: PBdMC were generated from eight peanut allergic and 10 non-allergic subjects. The molecular profile (cell surface receptor expression) was assessed using flow cytometry. The stimulus-response profile (histamine release induced by secretagogues, secretion of cytokines/chemokines and changes in miRNA expression following anti-IgE activation) was carried out with histamine release test, luminex multiplex assay and miRNA arrays.
Results: Expression of activating receptors (FcϵRI, CD48, CD88, CD117, and C3aR) on PBdMC was not different among peanut allergic and non-allergic subjects. Likewise, inhibitory receptors (CD32, CD200R, CD300a, and siglec-8) displayed comparable levels of expression. Both groups of PBdMC were unresponsive to substance P, compound 48/80 and C5a but released comparable levels of histamine when stimulated with anti-IgE and C3a. Interestingly, among the secreted cytokines/chemokines (IL-8, IL-10, IL-13, IL-23, IL-31, IL-37, MCP-1, VEGF, GM-CSF) PBdMC from peanut allergic subjects showed a different secretion pattern of IL-31 compared to non-allergic subjects. Investigating miRNA expression from resting or activated PBdMC revealed no significantly difference between peanut allergic and non-allergic subjects.
Conclusion: The molecular and stimulus-response profile revealed that PBdMC from peanut allergic subjects differently express IL-31 compared to non-allergic subjects. However, since only one altered parameter was found among 893 investigated, it is still questionable if the pathophysiological mechanisms of peanut allergy are revealed in PBdMC.
(© 2018 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje